LIVE Day Two – 13th Annual Personalized Medicine Conference, From Concept to the Clinic, November 14–16, 2017, Joseph B. Martin Conference Center, Harvard Medical School, 77 Avenue Louis Pasteur Boston, MA 02115
JOSEPH B. MARTIN CONFERENCE CENTER
HARVARD MEDICAL SCHOOL, BOSTON, MA 02115
Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston
will cover in REAL TIME the 13th Annual Personalized Medicine, From Concept to the Clinic, November 14–16, 2017, Joseph B. Martin Conference Center, Harvard Medical School, 77 Avenue Louis Pasteur Boston, MA 02115
In attendance, covering LIVE using Social Media
Aviva Lev-Ari, PhD, RN
Editor-in-Chief
http://pharmaceuticalintelligence.com
@pharma_BI
@AVIVA1950
#PMConf
Agenda · Part II NOVEMBER 16, 2017 · CONFERENCE PROGRAM | AGENDA
7:00 am Registration and Breakfast
8:00 am Opening Remarks
SPEAKER | Stephen L. Eck, M.D., Ph.D., President, CEO, Aravive Biologics; Board Chairman, Personalized Medicine Coalition
- 2005 at Pfizer new initiative on Personalized Medicine
- Left to go to Lilly – not to give a drug to Patients with KRAS mutation – beginning of PM
- Laxo – A molecular target to be found by diagnostics TEST — as a basis to develop a drug
- Pricing and value – dimensions of Value to society
- How PM is done today
8:10 am Clinical Adoption of Personalized Medicine: A Two-Part Discussion Pioneering health care providers have begun to explore the business models, operational processes, IT infrastructure and educational programs that are needed to catalyze the paradigm shift toward personalized medicine. This two-part session on clinical adoption will examine the strategic and day-to-day challenges clinical organizations face as they seek to integrate personalized medicine in clinical settings — and the solutions they employ to address those challenges.
SESSION CHAIR | Marcia A. Kean, M.B.A., Chairman, Strategic Initiatives, Feinstein Kean Healthcare
Discussion Part 1
8:15 am The Case for Personalized Medicine in the Clinic: The View From the Corner Office Inspiring an organizational commitment to a new way of practicing medicine requires visionary leadership. This fireside chat will highlight the viewpoints and approaches of leaders who are spearheading efforts to adopt personalized medicine at clinical institutions, with an eye on the value proposition for changing existing norms and practices.
MODERATOR | Howard L. McLeod, Pharm.D., Medical Director, The DeBartolo Family Personalized Medicine Institute, Chair, Department of Individualized Cancer Management, Senior Member, Division of Population Sciences, Moffitt Cancer Center; Board Member, Personalized Medicine Coalition
Jeffrey R. Balser, M.D., Ph.D., Dean, Vanderbilt University School of Medicine; President, CEO, Vanderbilt University Medical Center, Nashville, TN
- Vanderbilt University Medical Center [$500 Million in Grants] is a HealthCare System, split from Vanderbilt University School of Medicine [1200 Medical Residents], now they are like Partners
- BioMedical Informatics very strong at Vanderbilt University School of Medicine
- Jeffrey R. Balser, M.D., Ph.D. was first student of Dan, A pioneer in Personalized Medicine
- PM and Non-Oncology: PLAVIX – DSS when MD order drugs DSS trigger No PLAVIX to this patient, made second decision in real time by MDs
- Nashville – four flagship hospitals, largest HMO not for profit in the country
- PM at Vanderbilt University Medical Center – 25 drugs – given ONLY after Genomic sequencing
- Millianlian Diabetics NOT on Medicare, Analytics: iPhone telling patient what dishes to order since SYSTEM KNOWS BLOOD SUGER 24×7 – target care by Analytics
- Genomics paid by NIH
- PM Analytics is built at Vanderbilt University Medical Center said Jeffrey R. Balser, M.D., Ph.D., Dean, Vanderbilt University School of Medicine; President, CEO, Vanderbilt University Medical Center
- what is the economics benefit of Genomic sequencing: DSS on Drugs – Peterson is documenting drug class by economic benefit – bundle to show value
- Genomics based PM is on drugs — polimorthism – this drug will not work
- Disease counseling is harder than drug = wellness strategy is the Fututre
- Genomics based PM to be turned into Wellness Strategy – the path not yet knows said Jeffrey R. Balser, M.D., Ph.D., Dean, Vanderbilt University School of Medicine; President, CEO, Vanderbilt University Medical Center, Nashville, TN
- Research Investment is R&D, decisions made to guide all research and investment in PM initiative – not generating money. Pilot studies leads to grants. One study is on Economic benefit of PM
Ronald A. Paulus, M.D., M.B.A., President, CEO, Mission Health, NC, ex-Geisinger, CIO
- 8 most western counties in NC
- small group of Genetists:
- PM and Oncology and – Cancer therapy from a Genomics stand point
- PM and Non-Oncology – Drug-Drug interactions
- Clinicians needs actionable information
- Primary care practices to adopt PM – HOW, where, why? what will be out of pocket expense to the individual
- subsidization is a must
- payment dominates delivery of care, future PM from Genomics cost to patients
- Transform acceptability of PM suggested Ronald A. Paulus, M.D., M.B.A., President, CEO, Mission Health, NC, ex-Geisinger, CIO
Discussion Part 2
9:00 am Practicing Personalized Medicine: Lessons From the Front Lines To successfully integrate personalized medicine into a health system, administrators and clinicians must also design and implement new processes related to program infrastructure and informatics; help educate physicians and patients about the field; and inspire cultural change within the institution. During this panel discussion, a group of early adopters will share lessons learned from implementing pilot programs across the United States.
MODERATOR | Daryl Pritchard, Ph.D., Senior Vice President, Science Policy, Personalized Medicine Coalition
Bonnie J. Addario, Founder, Chair, Bonnie J. Addario Lung Cancer Foundation; Board Member, Personalized Medicine Coalition; Lung Cancer Survivor
Scott A. Beck, M.B.A., Administrator, Center for Individualized Medicine, Mayo Clinic, MN, AZ
- PM, Genomics sequencing, BioEthics, IT, Translational Perspective in Epi-genomics,
- Discovery to Translation Applicattions
- Pharmacy- Formulary – EMR – Champions from Disease areas to practice environment
- Testing offering, approve value
- 25 Projects: PharmacoGenomics Testing to patients, change drug before repeat endoscopy
Timothy Cannon, M.D., Clinical Director, Inova Schar Cancer Institute Molecular Tumor Board
- 5 hospital in VA,
- Precision Genomics Cancer Therapy
- Poor understanding of molecular results by MDs, Refractory Patients – no Forum to discuss other options
- Molecular Tumor Board for Inova Health System: 220 patients presented beyond Inova
- Oncologists had concerned that patients are aware of drug that MD can’t deliver to client
Peter Hulick, M.D., M.M.Sc., Medical Director, Center for Personalized Medicine, NorthShore University HealthSystem
- 4 hospitals – 950 MDs
- PCP to get engaged
- Neurology
- Genetic Assessment tool DSS offers PCP option for electronic ordering of the Genetic Testing, Results appear in Patients’ charts
- Proactive testing
- 20,000 patients in the system to be tested for pharmaco-genomics testing
Marc S. Williams, M.D., F.A.A.P., F.A.C.M.G., F.A.C.M.I., Director, Genomic Medicine Institute, Geisinger – Central PA
- 30% of providers are Geisinger the rest are not
- Genomics: PM — Microbiome bank – broad user consent: recontact and return results
- Genomics Medicine Institute – 2014 Partnership with Regeneron – genomics sequencing and profiling — all result to be used by Geisinger
- 170,000 patient consented – 90% responded, 8,000 sequences available
- 80 gene with potential actionability – interpretation by Scientists
- Pathologic calls return results –
- Clinical Genomics vs Physician specialist (i.e.,hypercholestoralemia), both in same place – paper and EMR
- Outcomes – tracking patients over decades – systems in place to capture the data
- Virtual Cycle Clinical data – dashboards were created to deliver results per week.
- 1/2 people do not need criteria
- Geisinger will disseminate internationally
10:15 am Networking Break (sponsored by Moffitt Cancer Center)
10:45 am Harvard Business School Case Study — Intermountain Healthcare: Pursuing Precision Medicine Intermountain has a long history of being at the forefront of health care quality improvement and the development of treatment protocols. In 2013, Intermountain Precision Genomics (IPG) was started with Dr. Lincoln Nadauld as its Executive Director. IPG focused on stage 4 cancer patients and performed three distinct functions: genomic sequencing, interpretation of sequencing results with recommendations for precision therapies, and drug acquisition and reimbursement. A paper published in February 2017 reported that in addition to having a higher quality of life, patients who received the targeted therapies had progression-free survival rates of almost twice as long as other patients. The purpose of our case discussion will be to assess these efforts, to consider their broader applicability and to review IPG’s plans for the future.
PRESENTER | Richard Hamermesh, D.B.A., Co-Faculty Chair, Harvard Business School Kraft Precision Medicine Accelerator
12:00 pm Overview of the International Landscape for Personalized Medicine
PRESENTER | Kristin Pothier, M.S., Global Head, Life Sciences, Parthenon-EY
- Precision Medicine in the Globe – stackholder ecosystem
- India
- Latin America
- USA
- Africa
- EU
- APAC
- Middle East
Regional Spotlight:
China – strength emerging 1.4 Billion people, 4.2 million annual incidence of Cancer – systemic challenges will limit access
Brazil – 440,000 cancer incidents a year, 207 Million Corporate, Hospital, Government, Academic research, collaboration vs competition, collaboration will win
Dubai – 28.5 Million population
Qatar –
UAE – Initiative to sequence the entire population, 6,000 done
Saudi Arabia
Middle East – 0.4 oncologist for 100,000
Summary – Unmet need, commitment is there, innovation and connectivity drive access, collaboration not competition – helps Precision medicine in emerging nations. Access to PM anywhere in the world suggested Kristin Pothier, M.S., Global Head, Life Sciences, Parthenon-EY
12:30 pm Bag Lunch
1:30 pm Personalized Medicine at FDA: An Inside Look at the Agency’s Priorities for the Field
INTRODUCTION | Cynthia A. Bens, Vice President, Public Policy, Personalized Medicine Coalition
KEYNOTE | Sean Khozin, M.D., M.P.H., Associate Director (Acting), Oncology Center of Excellence, FDA
- Advances of technology of biomarkers, disease indication
- Accelerated approval by FDA a collaborative of speeding the process
- companion diagnosis assays and drug or biologics
- FDA considers N of One, small samples, EGFR drug was approved in 2 1/2 years since Phase 1 of NDA
- New trial designs: reduce bias and alternative end points
- narrow criteria for participation, more personalized and more patient-centered
- innovation INFORMS at NIH Center of Excellence – data collection and analysis of multiple data types
- Biometric sensors collecting data on cancer patients
- collaboration with Academia, single arm vs randomized, decentralized
- devices are collecting data in clinical trials
- 21st Century – metastatic solid tumors – 900 patients: accommodated plan
- Lab developed Tests: new approach
- Efficiency, transparency
2:00 pm The Patient Perspective on Personalized Medicine
INTRODUCTION | Susan McClure, Founder, Publisher, Genome magazine; Board Member, Personalized Medicine Coalition
- Precision medicine and relevant information for Patients
- Genomic sequencing is the Opening Gate to PM
KEYNOTE | Bryce Olson, Global Marketing Director, Health and Life Sciences Group, Intel Corporation
- genome sequencing found his Pi3K Pathway – PIK3CA p.E54 – Anti Inhibitor for Pi3K = Precision Medicine
2:30 pm Patient 2.0: Exploring the Future of Personalized Medicine Many observers speculate that the coming wave of gene editing, gene therapy, direct-to-consumer genetic tests and the personalized use of wearables will change the psychology, sociology, economy and efficacy of health care. Informed by the previous panel discussions, this conversation will examine the future of personalized medicine and the merits of these emerging trends.
MODERATOR | Robert C. Green, M.D., M.P.H., Director, Genomes2People Research Program, Professor of Medicine (Genetics), Brigham and Women’s Hospital, Broad Institute and Harvard Medical School
- Neurologist first , Geneticist thereafter
- Platinum vs gold standard
- 59 genes will identify 80,000 will get the disease and 47,000 will never get the disease
- is the technology the reason for investment vs Family history
- pharmacogenomics can harm, if odds are so low than adherence will be lower
Sandro Galea, M.D., M.P.H., Dr.P.H., Dean, Robert A. Knox Professor, School of Public Health, Boston University
- Skeptical of societal aspects: race, 50% of the country health getting better vs 50% getting worse but enthusiast on technology
- US expense on Health care the highest in the World comes on the expense of housings, mental health, education – curative vs preventive care
- MDs are insentiviced to keep patients sick
- Folic Acid
- Nudge behavior
- invest in long livivng
Tom Miller, M.S., Founder, Managing Partner, GreyBird Ventures LLC
- duty to call up therapies that will not work, balance addressed by PM – diagnostics in PM
- clinical utility from patient selection for the therapy the patient will respond to
- fantasy: Medical decision making to be made to avoid un neccesary care
Michael Snyder, Ph.D., Stanford W. Ascherman Professor, Chair, Department of Genetics, Director, Center of Genomics and Personalized Medicine, Stanford University School of Medicine
- Personal sequencing for multiple etiologies
- rich people come to get sequenced
- libraries
- Providers to be incentivized if patients are health
3:30 pm Closing Remarks
SPEAKER | Edward Abrahams, Ph.D., President, Personalized Medicine Coalition
Leave a Reply